Outcomes of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer and severe renal dysfunction. Litt HK, Mamtani R, Chow RD. Urol Oncol 2026;44:118.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Litt HK, Mamtani R, Chow RD. Outcomes of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer and severe renal dysfunction. Urol Oncol 2026;44:118.
PMID: 41238476